Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Stock Short Interest Declines 47.9%

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 6,364 shares, a decrease of 47.9% from the August 31st total of 12,218 shares. Based on an average daily trading volume, of 2 shares, the short-interest ratio is currently 3,182.0 days.

Laboratorios Farmaceuticos Rovi Stock Performance

Shares of OTCMKTS LABFF remained flat at C$67.17 during midday trading on Wednesday. Laboratorios Farmaceuticos Rovi has a 12-month low of C$65.86 and a 12-month high of C$67.17. The stock has a 50-day moving average of C$66.79 and a 200 day moving average of C$66.15.

Laboratorios Farmaceuticos Rovi Company Profile

Laboratorios Farmacéuticos Rovi, SA is a Spain-based pharmaceutical company engaged in the research, development, manufacture and commercialization of prescription medicines and other healthcare products. The company focuses on specialty pharmaceuticals, with activities spanning proprietary drug development, marketing and pharmaceutical manufacturing services.

Rovi’s portfolio includes medicines for areas such as thrombosis and other hospital and specialist-care indications. Its products include bemiparin, marketed under the Hibor brand in various markets, as well as long-acting injectable treatments developed using its ISM drug-delivery technology, including products based on risperidone.

In addition to its own branded products, Rovi operates as a contract development and manufacturing organization, providing pharmaceutical manufacturing services, particularly for injectable medicines.